Leerink Swann Upgrades Intercept Pharmaceuticals (ICPT) to Outperform

FBR Capital Starts Intercept Pharmaceuticals (ICPT) at Underperform

FBR Capital initiates coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Underperform rating and a price target of $172.00.

Analyst Andrew Berens, M.D.said, " We believe investors are much too optimistic about the accessibility of the nonalcoholic steatohepatitis (NASH) market and the regulatory pathway to commercialization. We agree that NASH is... More

Summer Street Reaffirms Bullish Stance on Intercept Pharma (ICPT); Comments on FLINT Update

Summer Street affirms its Buy rating and $650 target price on Intercept Pharmaceuticals (Nasdaq: ICPT) following Q2 results and FLINT study update issued Monday night.

Analyst Jim Molloy made the following interpretations following Intercept's report:

-- Efficacy data looks great, fibrosis data a huge positive. OCA hit on the primary endpoint of a reduction in NAS scores, and while exact data remains embargoed until the AASLD meeting in November,... More

Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at BMO Capital Following FLINT Data

BMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $515 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following receipt of a draft manuscript for the FLINT OCA NASH trial authored by NIDDK.

Birchenough said, "We believe the results are better than expected with... More

Intercept Pharmaceuticals (ICPT) PT Lifted to $456 at Nomura Amid Positive Top-Line FLINT Data

Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT) and boosted his price target to $456.00 (from $323.00) ) following positive top-line FLINT data.

Somaiya commented, "The results greatly de-risk the regulatory process for OCA in NASH and could... More

Intercept Pharm (ICPT) Posts Q2 Loss of 79c/Share; Issues Positive FLINT Data

Intercept Pharm (NASDAQ: ICPT) reported Q2 EPS of ($0.79), which may not compare with the analyst estimate of ($0.12). Revenue for the quarter came in at $405.4 million versus the consensus estimate of $400 million.

Included in net income for the second quarter of 2014 is a $55.8 million non-cash gain recorded for the revaluation of all outstanding warrants which were exercised in April 2014.

Cash Position

As of June 30, 2014, Intercept had cash, cash equivalents and investment securities available for sale of approximately $299.0 million. In April 2014, Intercept completed an underwritten public offering of 1,000,000 shares of common stock, of which... More